Novel strategies in multiple myeloma
Henrik Gregersen, Valdas Peceliunas, Kari Remes, Fredrik Schjesvold, et al.
Conclusion: Maintenance therapy with carfilzomib and dexamethasone maintenance prolongs median time to progression with approximately 6 months following salvage ASCT in multiple myeloma.
Sagar Lonial, Niels W.C.J. van de Donk, Rakesh Popat, Jeffrey A. Zonder, et al.
Conclusion: IBER + DEX showed favorable efficacy and safety in heavily pretreated patients with RRMM who failed multiple prior therapies. This study is ongoing, including combinations of IBER with DARA or BORT.
James Abraham Malala, Glenn Willson Ng, Lucille Osias, Catherine Rosales
Conclusion: Our analysis still supports the use of zoledronic acid as a first line bone-targeted agent for MBD based on longer time to first SRE & lesser rates of the most common & dreaded complications such as hypocalcemia and jaw osteonecrosis, respectively. In addition, since denosumab doesn’t require renal function for use, our findings suggest that denosumab is an effective second-line agent for patients who has contraindications with zoledronic acid use due to renal dysfunction. Lastly, treatment of myeloma bone disease whichever agent doesn’t change the overall survival of multiple myeloma patients.
Paul G. Richardson, Albert Oriol, Alessandra Larocca, Paula Rodriguez Otero, et al.
Conclusion: Melflufen continues to have promising activity in pts with late-stage RRMM refractory to dara and/or pom and was generally well tolerated, with infrequent nonhematologic AEs and low rates of discontinuation due to AEs.
Cristina Gasparetto, Suzanne Lentzsch, Gary Schiller, Natalie Callander, et al.
Conclusion: Selinexor 100 mg QW can be combined safely with dara (per approved dosing) and dex to produce a deep and durable response warranting further investigation in pts with relapsed refractory MM. The ORR was 77% in pts who had not received prior dara or selinexor. Enrollment in the expansion arm is expected to be completed in March 2019 and full study results will be presented.